PM8002 + BNT327

PM8002 + BNT327 is an investigational combination drug composed of two monoclonal antibodies—PM8002 and BNT327—formulated as a **bispecific antibody targeting PD-L1 and VEGF-A**. This drug is designed for the treatment of advanced cancers including metastatic triple-negative breast cancer (TNBC), extensive-stage small cell lung cancer (ES-SCLC), and unresectable pleural and peritoneal mesothelioma. Mechanistically, it blocks **PD-L1**, an immune checkpoint protein enabling tumor immune evasion, and **VEGF-A**, which promotes tumor angiogenesis. By dually inhibiting these pathways, PM8002 + BNT327 enhances anti-tumor immune responses while also limiting the tumor's ability to generate new blood vessels. The antibody is administered intravenously, typically in combination with chemotherapy such as nab-paclitaxel or platinum-based regimens, in clinical trials. The developers are evaluating its safety and efficacy in multiple phase 2 and phase 3 clinical trials, with promising response rates reported in TNBC, ES-SCLC, and mesothelioma[1][2][3][5][7].

Brand names

PM8002 + BNT327

Other names

BNT327/PM8002